Anadrol,Buy Anadrol,Buy Steroids,Effects of Steroids
headerimage2
Home      |          Services      |     Resources      |     Site Map      |     Contact US
                  MENU
icon

Anadrol 50

icon Anadrol side effects
icon Buy anadrol
icon Anadrol for in
icon Anadrol cycle
icon Anadrol 50 oxymetholone
icon Anadrol 50 steroid
icon

Anadrol bold

icon Anadrol 75
icon Anadrol scion
icon Anadrol pill
icon Anadrol 50 side effects
   
  Featured Links
 
Anabolic Steroids
Buy Steroids
Buy Steroids
Steroid Abuse
   
Anadrol 50 oxymetholone :

Anadrol 50 oxymetholone is the U.S. brand name for oxymetholone, a very potent oral androgen. Since oxymetholone is quite reliable in its ability to increase red blood cell production, it showed great promise in treating cases of severe anemia. It turned out to be well suited for this purpose, and was popular for quite some time.  

Anadrol 50 oxymetholone drug is shown to have a much more direct effect on the red blood cell count, without the side effects of a strong androgen. Anadrol 50 is considered by many to be the most powerful steroid available, with results of this compound being extremely dramatic. A steroid novice experimenting with oxymetholone is likely to gain 20 to 30 pounds of massive bulk, and it can often be accomplished in less than 6 weeks, with only 50-100mg a day.  

Oxymetholone is a derivative of dihydrotestosterone, which gives it a structure that cannot be aromatized. As such, many have speculated as to what makes this hormone so troublesome in terms of estrogenic side effects. However we do find medical studies looking at this possibility. One such tested the progestational activity of various steroids including nandrolone, norethandrolone, methandrostenolone, testosterone and oxymetholone. 

Anadrol 50 oxymetholone is also a very potent androgen. This factor tends to produce many pronounced, unwanted androgenic side effects. Oily skin, acne and body/facial hair growth can be seen very quickly with this drug. Many individuals respond with severe acne, often requiring medication to keep it under control     

Anadrol 50 is the very strongest and at the same time, also the most effective oral steroid. The Anadrol 50 compound has an extremely high androgenic effect, which goes hand in hand with an extremely intense anabolic component. For this reason, dramatic gains in strength and muscle mass can be achieved in a very short time. An increase in body weight of 10 - 15 pounds or more in only 14 days is not un-usual.  

By the use of Anadrol 50, water retention is considerable, so that the muscle diameter quickly increases and the user gets a massive appearance within record time. Since the muscle cell draws a lot of water, the entire muscle system of most athletes looks smooth, in part even puffy. Anadrol does not cause a qualitative muscle gain but rather a quantitative one, which in the off-season is quite welcome. 

Anadrol "lubricates" the joints since water is stored there as well. On the one hand this is a factor in the enormous increase of strength and, on the other hand, it allows athletes with joint problems a painless workout. Power lifters in the higher weight classes are sold on Anadrol. A strict diet, together with the simultaneous intake of Nolvadex and Proviron, can significantly reduce water retention so that a distinct increase in the solid muscles is possible.  

By taking Anadrol the athlete experiences an enormous "pump effect" during the workout in the exercised muscles. The blood volume in the body is significantly elevated causing a higher blood supply to the muscles during workout. Anadrol increases the number of red blood cells, allowing the muscle to absorb more oxygen. The muscle thus has a higher endurance and performance level. 

The highly androgenic effect of Anadrol stimulates the regeneration of the body so that the often-feared "over-training" is unlikely. Anadrol helps more than any other steroid during dieting to maintain the muscle mass and to allow an intense workout. Many bodybuilders therefore use it up to about one week before a competition, solving the problem of water retention by taking anti-estrogens and diuretics so that they will appear bulky and hard when in the limelight.

CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
WASHINGTON, June 25, 2008 /PRNewswire-USNewswire/ -- The Congressional Budget Office (CBO) today released a cost analysis finding that the creation of an abbreviated pathway for follow-on biologics -- or biogenerics -- would save the federal...


Center for Communication Compliance Launches First Regulatory Resource, Training and Certification Portal for Healthcare Communicators
Government fines of $6 billion imposed on pharmaceutical industry for noncompliance Standardized, centralized, expert-reviewed site helps reduce risk, increase credibility, save time NEW YORK, June 25, 2008 - The first and only...


Concerned Shareholders of Biovail Seek Court Order Declaring Biovail AGM Illegally Convened;
Say Biovail seeing tide changing against management - with six million votes revoked - and no quoroum at meeting, secretly met to change rules TORONTO, June 25, 2008 /PRNewswire/ - The Concerned Shareholders of Biovail said that their lawyers will...


New Report: The Truth About Drug Innovation
NEW YORK, June 24, 2008- A new report co-authored by Manhattan Institute senior fellow Benjamin Zycher, and Joseph DiMasi, and Christopher-Paul Milne, researchers from the Tufts Center for the Study of Drug Development, examines case...


Savings Help the Medicine Go Down
Prescription drug coverage for low income seniors reduces Medicaid WALTHAM, Mass., June 24, 2008—A new study of state-subsidized pharmacy assistance programs showed that providing prescription drug coverage for low-income seniors reduces...


Use of Drug-Releasing Stents Associated With Decrease in Repeat Procedures to Unblock Coronary Arteries
CHICAGO, June 24, 2008—The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to...


Federal Action Needed to Fill Antibiotic Pipeline, Says the Alliance for the Prudent Use of Antibiotics
BOSTON, June 24, 2008 /PRNewswire-USNewswire/ -- Antibiotic resistance is one of the major public health threats of the 21st century and the focus of today's Senate hearing, Emergence of the Superbug: Antimicrobial Resistance in the US. Resistant...


Center for Public Integrity: Drug Industry Spent Record Amount Lobbying in '07 Over a Billion Dollars Spent in the Last 10 Years
WASHINGTON, D.C., June 24, 2008 - Pharmaceutical manufacturers and their trade groups racked up another banner year on Capitol Hill, spending a record $168 million on lobbying in 2007, a 32 percent jump over 2006, according to a Center for Public...


Barrier Therapeutics to Merge Into Stiefel Laboratories
Acquisition to Enhance Industry Leader's Dermatological Portfolio CORAL GABLES, Fla., June 23, 2008 /PRNewswire/ -- Stiefel Laboratories Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced it has...


FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane
Clinical Studies Expected to Restart in Second Half 2008 BERKELEY HEIGHTS, N.J., June 23, 2008 /PRNewswire-FirstCall/ -- Genta Incorporated announced that the Company has received notification from the U.S. Food and Drug Administration (FDA)...


GTC Biotherapeutics Enters Into $257 Million Agreement with Ovation Pharmaceuticals to Develop and Market ATryn in the U.S.
FRAMINGHAM, MA - June 23, 2008 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and Ovation Pharmaceuticals, Inc. (“OVATION”) have entered into a collaboration agreement to develop and market ATryn in the United...


Should Doctors Be 'Selling' Drugs for the Pharmaceutical Industry?
Feature: Key opinion leaders -- independent experts or drug representatives in disguise? LONDON, June 19, 2008-Are senior doctors who help drug companies sell their drugs independent experts or just drug representatives in disguise, asks Ray...


Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jun 20, 2008 - Merck & Co., Inc. today provided an update on the regulatory status in the United States of its investigational medicines MK-0524A (ER niacin/ laropiprant) and MK-0524B...


YM BioSciences Announces FDA Lifts Clinical Hold on Aerolef and Clearance of a Phase II Clinical Trial
- Dr. Ali Raza To Lead Further Development Of AeroLEF As President Of AeroLEF Division - MISSISSAUGA, ON, June 19, 2008 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated...


Canada's Research-Based Pharmaceutical Companies Invested Over a Billion Dollars in Research and Development (R&D) in 2007 But Opportunities Exist for Further Growth, Says Rx&D
SAN DIEGO, CA, June 19 /CNW Telbec/ - Canada's Research-Based Pharmaceutical Companies President Russell Williams issued the following statement from BIO 2008 today in reaction to the release of the Patented Medicine Prices Review Board's (PMPRB)...


Intas Biopharmaceuticals Ltd. Acquires US-based BPD Inc.
SAN DIEGO--(BUSINESS WIRE)--Jun 20, 2008 - India's leading biopharmaceutical company, Intas Biopharmaceuticals Ltd. (IBPL, www.intasbiopharma.co.in), has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD...


Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Jun 18, 2008 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today issued the following statement on the outcome of today's meeting of the U.S. Food...


Johnson & Johnson Nordic AB Acquires Amic
Gains Access to In Vitro Diagnostic Technologies in Development for Use in Point-of-Care Settings SOLLENTUNA, Sweden, June 18, 2008 /PRNewswire/ -- Johnson & Johnson Nordic AB, a Johnson & Johnson company, today announced the acquisition of...


Majority of Americans Support Legislative Action to Disclose Pharmaceutical Company Gifts to Physicians
BOSTON--(BUSINESS WIRE)--Jun 18, 2008 - A majority of Americans (64%) say that it is important to know their physician's financial ties to pharmaceutical companies and 68% would support legislation requiring pharmaceutical companies to disclose...


Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion
Sophisticated Infrastructure and Skilled Manpower Support Cutting-Edge Manufacturing Activities SAN DIEGO, June 18, 2008 /Xinhua-PRNewswire/ -- Singapore has firmly established itself as a leading manufacturing hub in Asia with its strong track...


EMEA Recommends Information on Lung Cancer Cases to Be Included in Exubera Product Information
LONDON, 17 June 2008--The European Medicines Agency (EMEA) has recommended that the product information for Exubera be updated with new information on cases of lung cancer seen in patients taking the medicine. Exubera, from Pfizer Limited, is a...


Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of Kosan Biosciences Incorporated
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 18, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino review period for its tender offer for Kosan Biosciences Incorporated (NASDAQ: KOSN) ("Kosan") has...


FDA Warns Individuals and Firms to Stop Selling Fake Cancer 'Cures'
Fraudulent claims on Internet sites ROCKVILLE, Md., June 17, 2008--Warning Letters have been sent to 23 U.S. companies and two foreign individuals marketing a wide range of products fraudulently claiming to prevent and cure cancer, according to...


FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., June 17, 2008 /PRNewswire/ -- Centocor, Inc. announced today that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) has unanimously recommended the approval of ustekinumab,...


Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
Ranbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days Exclusivity From Nov. 30, 2011 GURGAON, Harayana, India and PRINCETON, N.J., June 18, 2008 /PRNewswire/ -- Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has entered...


Sanofi-aventis Intends to Make a Competing Bid of CzK 1,050 in Cash Per Share for Zentiva
PARIS, France, June 18, 2008 - Sanofi-aventis intends to make a Competing Bid for all issued and outstanding ordinary shares in the share capital of Zentiva at an offer price of CZK 1,050 in cash per Share. The Competing Bid values Zentiva at 40,043...


Statement Regarding Official Publication of Voluntary Takeover Offer by Anthiarose Limited
Zentiva N.V. PRAGUE, CZ and LONDON, June 17, 2008 - Zentiva N.V. notes the official publication today by Anthiarose Limited, a wholly owned subsidiary of PPF Group N.V., of its unsolicited voluntary takeover offer to acquire Zentiva N.V....


Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set Of Services
NEW YORK, June 17, 2008— Among US primary care physicians, Novartis earns the highest sales rep relationship scores, followed by Pfizer, Merck, GlaxoSmithKline and Sanofi-Aventis, according to new research from TNS Healthcare. Novartis...


Decision Resources, Inc. Acquires Manhattan Research
Acquisition Expands Decision Resources, Inc.'s Portfolio to Include Global Physician and Consumer Digital Market Research WALTHAM, Mass. and NEW YORK, June 17, 2008 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research...


Reps. Dingell, Stupak Welcome PhRMA Invitation to Discuss DTC Regulations
WASHINGTON, June 16, 2008-Leaders of the Committee on Energy and Commerce today responded to four pharmaceutical companies and their trade association regarding their business practices related to Direct-to-Consumer (DTC) advertising. On May 20,...


Boehringer Ingelheim to Acquire Actimis Pharmaceuticals
INGELHEIM, Germany, SAN DIEGO, United States, June 17, 2008 - Boehringer Ingelheim GmbH today announced an agreement to acquire Actimis Pharmaceuticals, Inc., a privately owned biotech company based in San Diego. The acquisition will occur through a...


IMS Health Reports Global Biotech Sales Grew 12.5 Percent in 2007, Exceeding $75 Billion
NORWALK, Conn.--(BUSINESS WIRE)--June 17, 2008--Global prescription sales of biotech drugs increased 12.5 percent in 2007 to more than $75 billion, according to a new report by IMS Health (NYSE: RX), the world's leading provider of market...


FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs
ROCKVILLE, Md., June 16, 2008--The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to...


Information for Healthcare Professionals: Antipsychotics
ROCKVILLE, Md., June 16, 2008-FDA ALERT [6/16/2008]: FDA is notifying healthcare professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated...


Biovail Recommends Shareholders Vote to Move Forward from the Melnyk Lost Years
TORONTO--(BUSINESS WIRE)--Jun 16, 2008 - Biovail Corporation (NYSE:BVF)(TSX:BVF) today issued a second letter to shareholders, reminding them of the impending deadline to vote for the Biovail nominees to the Board of Directors at the Company's June...


Ore Pharmaceuticals Focuses Resources on Development of Repositioned Compounds
GAITHERSBURG, Md.--(BUSINESS WIRE)--Jun 16, 2008 - Ore Pharmaceuticals Inc. (NASDAQ:ORXED) announced today a new alignment of corporate resources. Henceforward, the Company will invest its resources in clinical development and business development...


Novartis Vaccines and Diagnostics S.r.l. Withdraws Its Marketing Authorisation Application for the Pre-pandemic Vaccine Aflunov
LONDON, June 16, 2008-The European Medicines Agency (EMEA) has been formally notified by Novartis Vaccines and Diagnostics S.r.l. of its decision to withdraw the application for a centralised marketing authorisation for the pre-pandemic vaccine...


Drug Makers Differ Strongly in Policies for Low-income Countries
Index lets investors select most socially responsible producers HAARLEM, THE NETHERLANDS (June 16, 2008) — The world's largest pharmaceutical companies differ strongly in their efforts to provide millions of people in low-income...


Sen. Grassley Seeks FDA Scrutiny of Paxil and Suicide Risk
WASHINGTON, June 12, 2008 - Senator Chuck Grassley has asked the Food and Drug Administration to carefully scrutinize information it received from drug maker GlaxoSmithKline about the anxiety disorder drug Paxil, based on the contents of a...


FDA, European Medicines Agency to Consider Additional Test Results When Assessing New Drug Safety
Collaborative Effort by FDA and EMEA Expected to Yield Additional Safety Data ROCKVILLE, Md., June 12, 2008--In the first use of a framework allowing submission of a single application to the two agencies, the Food and Drug Administration (FDA) and...


Home  |    Services   |   Resources   |   Site Map   |   Contact Us
Copy rights© reserved by ianadrol.com